Overview

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

Status:
RECRUITING

Trial end date:
2028-11-06

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.

Phase:

PHASE3

Details

Lead Sponsor:

Alexion Pharmaceuticals, Inc.

Treatments:

ravulizumab